Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 2, 2007, Pages 113-118

  Tan, Henkie P ^a   Shapiro, Ron ^a   Tom, Kusum ^a   Thai, Ngoc ^a   Marsh, Wallis ^a   Basu, Amit ^a   Marcos, Amadeo ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Campath; Complication; Delayed graft function; Economics; Infection; Laparoscopy; Prograf; Right lobe donor hepatectomy; Steroid free

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; COTRIMOXAZOLE; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

EID: 34247580226     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.2.113     Document Type: Article

References (25)

1. Tan HE Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemutuzumab induction and tacrolimus monotherapy. Am J. Transplant. 6, 2409-2417 (2006).
2. Tan HP, Marsh W Marcos A. Liver resection using a saline-linked radiofrequency dissecting seater for transection of the liver. J Am. Coll. Surg. 201, 152 (2005).
3. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J. Am. Coll. Surg. 200, 505-515 (2005).
4. Tan HP, Kaczorowski DJ, Basu. A et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation 78, 1683-1688 (2004).
5. Tan HP, Kaczorowski DJ, Basu A et al. Steroid-firee tacrolimus monotherapy following pretransplant thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transpl. Proc. 37, 4235-4240 (2005).
6. Shapiro R, Ellis D, Tan HP et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr. 148, 813-818 (2006).
7. Shapiro R, Jordan ML, Basu A et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann. Surg. 238, 520-525 (2003).
8. Basu A, Ramkumar M, Tan HP et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transpl. Proc. 37, 923-926 (2005).
9. Hill P, Gagliardini E, Ruggenenti P, Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol. Dial. Transplant. 20, 1741-1744 (2005).
10. Knechtle SJ. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr. Transplant. 8, 106-112 (2004)
11. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76(1), 120-129 (2003).
12. Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3, 722-730 (2003).
13. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am. J. Transplant. 5, 1347-1353 (2005).
14. Knechtle SJ, Fernandez LA, Pirsch JD et at. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 136, 754-760(2004).
15. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am. J Transplant. 5, 3009-3014 (2005).
16. Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - long-term results. Am. J. Transplant. 5, 2539-2548 (2005).
17. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenotate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80,457-465 (2005).
18. McCurry Y, lacano A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J. Thorac. Cardiovasc. Surg. 130, 528-537 (2005).
19. Tzakis A, Kato T, Nishida S et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation 75, 1227 (2003).
20. Gruessner RWG, Kandaswamy R, Humar A et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 79(9), 1184 (2005).
21. Tryphonopoulos P Madariaga JR, Kato T et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc. 37, 1203 (2005).
22. Starzl TE, Demetris AJ, Murase N et al. Cell migration, chimerism, and graft acceptance. Lancet 339, 1579-1582 (1992).
23. Starzl TE, Demetris AJ, Thicco M et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatogy 17,1127-1152 (1993).
24. Abu-Elmagd K. Intestinal transplantation for short gut syndrome and gut failure:rewarding outcomes and current consensus. Gastroterology 130(2),132-137 (2006).
25. Thai NL, Khan A. Tom K et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one and two-year outcomes. Tranplantation 82(12),1621-1624 (2006).